Asthma Medicine Hailed as Effective Treatment for COVID-19
|
By HospiMedica International staff writers Posted on 13 Jul 2020 |

Image: Asthma Medicine Hailed as Effective Treatment for COVID-19 (Photo courtesy of Queensland University of Technology).
Budesonide, a medicine used to help prevent the symptoms of asthma, is being touted as the “silver bullet” for COVID-19.
Budesonide, a corticosteroid or steroid, reduces the severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. Daily use of inhaled budesonide reduces the number and severity of asthma attacks, although it cannot provide relief from an asthma attack that is already underway. Dr. Richard Bartlett, a US doctor, believes that budesonide, otherwise known as the brand name Pulmicor, can successfully treat the coronavirus. Dr. Bartlett claims to have used inhaled, generic budesonide to cure several COVID-19 patients who have vouched for his treatment.
Now, researchers from the Queensland University of Technology (QUT Brisbane, Australia) and the University of Oxford (Oxford, UK) are collaborating to test common asthma inhalers as a treatment for COVID-19 infection. The STOIC (STerOids In COVID-19) trial will look at whether asthma inhalers given to people with early stage COVID-19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. Some patients will be given budesonide, while others will be given a placebo. Recruitment for the trial has begun and the researchers will be coordinating trial data analysis, modelling of pathological mechanisms and building COVID-19 maths models to explain and use the clinical trial data to optimize patient treatment. Mathematical modelling by the STOIC study team suggests that the earlier the inhaled steroid treatment is applied, the more people can be stopped from becoming sick.
“Ideally it may be that the corticosteroid therapy would be given to anyone with a new, dry cough, and while they are awaiting their COVID test results,” said associate Professor Nicolau, from the QUT Science and Engineering Faculty School of Mathematical Sciences.
Related Links:
Queensland University of Technology
University of Oxford
Budesonide, a corticosteroid or steroid, reduces the severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. Daily use of inhaled budesonide reduces the number and severity of asthma attacks, although it cannot provide relief from an asthma attack that is already underway. Dr. Richard Bartlett, a US doctor, believes that budesonide, otherwise known as the brand name Pulmicor, can successfully treat the coronavirus. Dr. Bartlett claims to have used inhaled, generic budesonide to cure several COVID-19 patients who have vouched for his treatment.
Now, researchers from the Queensland University of Technology (QUT Brisbane, Australia) and the University of Oxford (Oxford, UK) are collaborating to test common asthma inhalers as a treatment for COVID-19 infection. The STOIC (STerOids In COVID-19) trial will look at whether asthma inhalers given to people with early stage COVID-19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. Some patients will be given budesonide, while others will be given a placebo. Recruitment for the trial has begun and the researchers will be coordinating trial data analysis, modelling of pathological mechanisms and building COVID-19 maths models to explain and use the clinical trial data to optimize patient treatment. Mathematical modelling by the STOIC study team suggests that the earlier the inhaled steroid treatment is applied, the more people can be stopped from becoming sick.
“Ideally it may be that the corticosteroid therapy would be given to anyone with a new, dry cough, and while they are awaiting their COVID test results,” said associate Professor Nicolau, from the QUT Science and Engineering Faculty School of Mathematical Sciences.
Related Links:
Queensland University of Technology
University of Oxford
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read moreSurgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








